"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
Multiple myeloma is a form of blood cancer that p"...
VELCADE® (bortezomib) is indicated for the treatment of patients with multiple myeloma.
Mantle Cell Lymphoma
VELCADE is indicated for the treatment of patients with mantle cell lymphoma.
DOSAGE AND ADMINISTRATION
General Dosing Guidelines
The recommended starting dose of VELCADE is 1.3 mg/m² . VELCADE may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL [see Reconstitution/Preparation for Intravenous and Subcutaneous Administration].
VELCADE retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with VELCADE and who have relapsed at least 6 months after completing prior VELCADE treatment. Treatment may be started at the last tolerated dose [see Dosage and Dose Modifications for Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma].
When administered intravenously, VELCADE is administered as a 3 to 5 second bolus intravenous injection. VELCADE is for intravenous or subcutaneous use only. VELCADE should not be administered by any other route.
Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.
Dosage In Previously Untreated Multiple Myeloma
VELCADE is administered in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in Table 1. In Cycles 1-4, VELCADE is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5-9, VELCADE is administered once weekly (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of VELCADE.
Table 1: Dosage Regimen for
Patients with Previously Untreated Multiple Myeloma
|VELCADE (1.3 mg/m²)||Day 1||—||—||Day 4||Day 8||Day 11||rest period||Day 22||Day 25||Day 29||Day 32||rest period|
|Melphalan(9 mg/m²) Prednisone(60 mg/m )||Day 1||Day 2||Day 3||Day 4||--||--||rest period||--||--||--||--||rest period|
|Once Weekly VELCADE (Cycles 5-9 when used in combination with Melphalan and Prednisone)|
|VELCADE (1.3 mg/m²)||Day 1||--||--||Day 8||rest period||Day 22||Day 29||rest period|
|Melphalan(9 mg/m ) Prednisone(60 mg/m )||Day 1||Day 2||Day 3||Day 4||--||--||rest period||--||--||--||--||rest period|
Dose Modification Guidelines For VELCADE When Given In Combination With Melphalan And Prednisone
Prior to initiating any cycle of therapy with VELCADE in combination with melphalan and prednisone:
- Platelet count should be at least 70 x 109/L and the absolute neutrophil count (ANC) should be at least 1.0 x 109/L
- Non-hematological toxicities should have resolved to Grade 1 or baseline
Table 2: Dose Modifications during Cycles of
Combination VELCADE, Melphalan and Prednisone Therapy
|Toxicity||Dose modification or delay|
|Hematological toxicity during a cycle: If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle||Consider reduction of the melphalan dose by 25% in the next cycle|
|If platelet count is not above 30 x 109/L or ANC is not above 0.75 x 109/L on a VELCADE dosing day (other than day 1)||Withhold VELCADE dose|
|If several VELCADE doses in consecutive cycles are withheld due to toxicity||Reduce VELCADE dose by 1 dose level (from 1.3 mg/m² to 1 mg/m², or from 1 mg/m² to 0.7 mg/m²)|
|Grade 3 or higher non-hematological toxicities||Withhold VELCADE therapy until symptoms of toxicity have resolved to Grade 1 or baseline. Then, VELCADE may be reinitiated with one dose level reduction (from 1.3 mg/m² to 1 mg/m², or from 1 mg/m² to 0.7 mg/m²). For VELCADE-related neuropathic pain and/or peripheral neuropathy, hold or modify VELCADE as outlined in Table 5.|
For information concerning melphalan and prednisone, see manufacturer's prescribing information.
Dose modifications guidelines for peripheral neuropathy are provided [see Dose Modifications for Peripheral Neuropathy].
Dosage In Previously Untreated Mantle Cell Lymphoma
VELCADE (1.3 mg/m²) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (VcR-CAP) for six 3-week treatment cycles as shown in Table 3. VELCADE is administered first followed by rituximab. VELCADE is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period on Days 12-21. For patients with a response first documented at cycle 6, two additional VcR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of VELCADE.
Table 3: Dosage Regimen for
Patients with Previously Untreated Mantle Cell Lymphoma
|VELCADE (1.3 mg/m²)||Day 1||--||--||Day 4||--||Day 8||Day 11||rest period|
|Rituximab (375 mg/m²) Cyclophosphamide (750 mg/m ) Doxorubicin (50 mg/m )||Day 1||--||--||--||--||rest period|
|Prednisone (100 mg/m )||Day 1||Day 2||Day 3||Day 4||Day 5||--||--||rest period|
|aDosing may continue for 2 more cycles (for a total of 8 cycles) if response is first seen at cycle 6.|
Dose Modification Guidelines For VELCADE When Given in Combination With Rituximab, Cyclophosphamide, Doxorubicin And Prednisone
Prior to the first day of each cycle (other than Cycle 1):
- Platelet count should be at least 100 x 109/L and absolute neutrophil count (ANC) should be at least 1.5 x 109/L
- Hemoglobin should be at least 8 g/dL (at least 4.96 mmol/L)
- Non-hematologic toxicity should have recovered to Grade 1 or baseline
Interrupt VELCADE treatment at the onset of any Grade 3 hematologic or non-hematological toxicities, excluding neuropathy [see Table 5 and WARNINGS AND PRECAUTIONS]. For dose adjustments, see Table 4 below.
Table 4: Dose Modifications
on Days 4, 8, and 11 during Cycles of Combination VELCADE, Rituximab,
Cyclophosphamide, Doxorubicin and Prednisone Therapy
|Toxicity||Dose modification or delay|
||Withhold VELCADE therapy for up to 2 weeks until the patient has an ANC at or above 0.75 x 109/L and a platelet count at or above 25 x 109/L.
|Grade 3 or higher non-hematological toxicities||Withhold VELCADE therapy until symptoms of the toxicity have resolved to Grade 2 or better. Then, VELCADE may be reinitiated with one dose level 2 2 reduction (from 1.3 mg/m to 1 mg/m , or from 1 mg/m² to 0.7 mg/m²).
For VELCADE-related neuropathic pain and/or peripheral neuropathy, hold or modify VELCADE as outlined in Table 5.
For information concerning rituximab, cyclophosphamide, doxorubicin and prednisone, see manufacturer's prescribing information.
Dosage And Dose Modifications For Relapsed Multiple Myeloma And Relapsed Mantle Cell Lymphoma
VELCADE (1.3 mg/m²/dose) is administered twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, VELCADE may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35) [see Clinical Studies]. At least 72 hours should elapse between consecutive doses of VELCADE.
Patients with multiple myeloma who have previously responded to treatment with VELCADE (either alone or in combination) and who have relapsed at least 6 months after their prior VELCADE therapy may be started on VELCADE at the last tolerated dose. Retreated patients are administered VELCADE twice weekly (Days 1, 4, 8, and 11) every three weeks for a maximum of 8 cycles. At least 72 hours should elapse between consecutive doses of VELCADE. VELCADE may be administered either as a single agent or in combination with dexamethasone [see Clinical Studies].
VELCADE therapy should be withheld at the onset of any Grade 3 non-hematological or Grade 4 hematological toxicities excluding neuropathy as discussed below [see WARNINGS AND PRECAUTIONS]. Once the symptoms of the toxicity have resolved, VELCADE therapy may be reinitiated at a 25% reduced dose (1.3 mg/m²/dose reduced to 1 mg/m²/dose; 1 mg/m²/dose reduced to 0.7 mg/m²/dose).
For dose modifications guidelines for peripheral neuropathy see section on Dose Modifications for Peripheral Neuropathy above.
Dose Modifications For Peripheral Neuropathy
Starting VELCADE subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy. Patients with pre-existing severe neuropathy should be treated with VELCADE only after careful risk-benefit assessment.
Patients experiencing new or worsening peripheral neuropathy during VELCADE therapy may require a decrease in the dose and/or a less dose-intense schedule.
For dose or schedule modification guidelines for patients who experience VELCADE-related neuropathic pain and/or peripheral neuropathy see Table 5.
Table 5: Recommended Dose Modification for VELCADE
related Neuropathic Pain and/or PeripheralSensory or Motor Neuropathy
|Severity of Peripheral Neuropathy Signs and Symptoms*||Modification of Dose and Regimen|
|Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) without pain or loss of function||No action|
|Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental Activities of Daily Living (ADL)**)||Reduce VELCADE to 1 mg/m²|
|Grade 2 with pain or Grade 3 (severe||Withhold VELCADE therapy until toxicity|
|symptoms; limiting self care ADL ***)||resolves. When toxicity resolves reinitiate with a reduced dose of VELCADE at 0.7 mg/m² once per week.|
|Grade 4 (life-threatening consequences; urgent intervention indicated)||Discontinue VELCADE|
|*Grading based on NCI Common
Terminology Criteria CTCAE v4.0
**Instrumental ADL: refers to preparing meals, shopping for groceries or clothes, using telephone, managing money etc;
***Self care ADL: refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden
Dosage In Patients With Hepatic Impairment
Patients with mild hepatic impairment do not require a starting dose adjustment and should be treated per the recommended VELCADE dose. Patients with moderate or severe hepatic impairment should be started on VELCADE at a reduced dose of 0.7 mg/m² per injection during the first cycle, and a subsequent dose escalation to 1.0 mg/m²or further dose reduction to 0.5 mg/m² may be considered based on patient tolerance (see Table 6) [see Use in Specific Populations and CLINICAL PHARMACOLOGY].
Table 6: Recommended Starting Dose Modification for
VELCADE in Patients with Hepatic Impairment
|Bilirubin Level||SGOT (AST) Levels||Modification of Starting Dose|
|Mild||Less than or equal to 1.0x ULN||More than ULN||None|
|More than 1.0x-1.5x ULN||Any||None|
|Moderate||More than 1.5x-3x ULN||Any||Reduce VELCADE to 0.7 mg/m² in the first cycle. Consider dose escalation to 1.0 mg/m² or further dose reduction to 0.5 mg/m in subsequent cycles based on patient tolerability.|
|Severe||More than 3x ULN||Any|
|Abbreviations: SGOT = serum
glutamic oxaloacetic transaminase;
AST = aspartate aminotransferase; ULN = upper limit of the normal range.
The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required. Caution should be used in calculating the dose to prevent overdose [see Reconstitution/Preparation for Intravenous and Subcutaneous Administration].
When administered subcutaneously, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated.
If local injection site reactions occur following VELCADE administration subcutaneously, a less concentrated VELCADE solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously [see Reconstitution/Preparation for Intravenous and Subcutaneous Administration]. Alternatively, the intravenous route of administration should be considered [see Reconstitution/Preparation for Intravenous and Subcutaneous Administration].
VELCADE is an antineoplastic. Procedures for proper handling and disposal should be considered [see HOW SUPPLIED/Storage and Handling].
Reconstitution/Preparation For Intravenous And Subcutaneous Administration
Proper aseptic technique should be used. Reconstitute only with 0.9% sodium chloride. The reconstituted product should be a clear and colorless solution.
Different volumes of 0.9% sodium chloride are used to reconstitute the product for the different routes of administration. The reconstituted concentration of bortezomib for subcutaneous administration (2.5 mg/mL) is greater than the reconstituted concentration of bortezomib for intravenous administration (1 mg/mL). Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered [see Administration Precautions].
For each 3.5 mg single-use vial of bortezomib reconstitute with the following volume of 0.9% sodium chloride based on route of administration (Table 7):
Table 7: Reconstitution
Volumes and Final Concentration for Intravenous and Subcutaneous Administration
|Route of administration||Bortezomib (mg/vial)||Diluent (0.9% Sodium Chloride)||Final Bortezomib concentration (mg/mL)|
|Intravenous||3.5 mg||3.5 mL||1 mg/mL|
|Subcutaneous||3.5 mg||1.4 mL||2.5 mg/mL|
Dose must be individualized to prevent overdosage. After determining patient body surface area (BSA) in square meters, use the following equations to calculate the total volume (mL) of reconstituted VELCADE to be administered:
- Intravenous Administration [1 mg/mL concentration]
VELCADE dose (mg/m²) x patient BSA (m²) 1 mg /mL= Total VELCADE volume (mL) to be administered
- Subcutaneous Administration [2.5 mg/mL concentration]
VELCADE dose (mg/m²) x patient BSA (m²) 2.5 mg /mL= Total VELCADE volume (mL) to be administered
Stickers that indicate the route of administration are provided with each VELCADE vial. These stickers should be placed directly on the syringe of VELCADE once VELCADE is prepared to help alert practitioners of the correct route of administration for VELCADE.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If any discoloration or particulate matter is observed, the reconstituted product should not be used.
Stability: Unopened vials of VELCADE are stable until the date indicated on the package when stored in the original package protected from light.
VELCADE contains no antimicrobial preservative. Reconstituted VELCADE should be administered within 8 hours of preparation. When reconstituted as directed, VELCADE may be stored at 25°C (77°F). The reconstituted material may be stored in the original vial and/or the syringe prior to administration. The product may be stored for up to 8 hours in a syringe; however, total storage time for the reconstituted material must not exceed 8 hours when exposed to normal indoor lighting.
Dosage Forms And Strengths
Each single-use vial of VELCADE contains 3.5 mg of bortezomib as a sterile lyophilized white to off-white powder.
Storage And Handling
VELCADE® (bortezomib) for Injection is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder.
3.5 mg single use vial
Unopened vials may be stored at controlled room temperature 25°C (77°F); excursions permitted from 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Retain in original package to protect from light.
Follow guidelines for handling and disposal for cytotoxic drugs, including the use of gloves and other protective clothing to prevent skin contact1.
1. “OSHA Hazardous Drugs” (refer to antineoplastic weblinks including OSHA Technical Manual). OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
Distributed and Marketed by: Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, MA 02139. Revised: Sep 2015This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/9/2015
Additional Velcade Information
Velcade - User Reviews
Velcade User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.